FGFR1 and breast carcinoma: Using a more traditional phase 1 clinical trial design, futibatinib, an orally bioavailable, irreversible inhibitor of FGFR1–4 demonstrated an overall response rate of 13% across several solid tumour types, including breast cancer [240].